Home › Blog › Weight Loss › UK Statistics 2026

Weight Loss Injections UK Statistics 2026: 70+ Verified Data Points on Mounjaro, Wegovy, the NHS Rollout and the Private Market

The UK weight loss injection market has grown faster than almost any other area of British healthcare in the past three years. This guide compiles the most reliable published data available on who is using these medicines, what they are paying, how the NHS rollout is progressing, and how many people stop treatment — with every figure attributed to its primary source.

The UK weight loss injection market at a glance

Overview: the UK weight loss injection market in 2026

The UK weight loss injection market has changed at almost unprecedented speed. In 2022, the number of UK adults accessing GLP-1 medications for weight management was in the tens of thousands. By July 2025 it had crossed two million — almost entirely driven by private demand, in a market the NHS rollout has so far only minimally penetrated.

This guide compiles and contextualises the most reliable published data available on UK weight loss injection use in 2026 — from the UCL Smoking Toolkit Study, IQVIA prescription supply data, BMJ Freedom of Information investigations, NHS England reports, MHRA enforcement data and NICE technology appraisal documentation.

Every figure is cited with its primary source. Where figures conflict between sources — as they frequently do, because of differing methodologies — both are noted and the difference explained. The guide is reviewed quarterly.

How many people use weight loss injections in the UK?

The headline adoption figure depends on whose methodology you use. These are the key data points from the most authoritative sources.

Why the figures differ

The UCL Smoking Toolkit Study (1.6 million) uses nationally representative survey self-reports — people who say they have used a weight loss drug. IQVIA’s figure (2 million+) counts dispensed prescription packs from pharmacy claims data. The two methodologies capture different things: survey data reflects patients who identify as users, claims data counts actual dispensings. Both are valid, and both show the same direction of travel — rapid, sustained growth driven almost entirely by private demand.

Mounjaro vs Wegovy: UK market share data

Which medicine UK patients actually use is now well documented from several independent sources.

What drove Mounjaro’s dominance

Mounjaro reached market dominance despite launching later than Wegovy in the UK. The main drivers were the head-to-head trial evidence, a substantial social media presence, and early adoption among higher-income patients with more tolerance for the price premium. The September 2025 list price increase created a price-sensitivity inflection point, and some patients moved to Wegovy — particularly after the January 2026 MHRA approval of the higher 7.2mg semaglutide dose narrowed the gap.

On the trial evidence: SURMOUNT-5 compared the two directly in 751 adults with obesity and without diabetes over 72 weeks, finding mean weight reduction of approximately 20.2% with tirzepatide against approximately 13.7% with semaglutide. That is a real difference in group averages, but it does not predict which medicine suits an individual — tolerability, medical history, cost and availability all bear on that.

NHS vs private: the two parallel realities

The UK weight loss injection market operates as two almost entirely separate systems — an NHS pathway open to a small, tightly restricted population, and a private market of over two million patients that has grown largely without NHS involvement.

NHS Mounjaro rollout: the data behind the headlines

The NHS tirzepatide rollout in England began on 23 June 2025 following NICE TA1026. The early data describes a rollout that is, in clinical terms, barely scratching the surface of the eligible population — by design rather than by failure.

Why the rollout is so slow

The restricted initial eligibility was a deliberate commissioning decision, intended to manage the budget impact of a medicine NICE estimated would cost the NHS in the region of £900 million a year at full rollout. The phased approach is a compromise between clinical benefit and fiscal capacity. In practice it means the large majority of people who meet the licensed criteria cannot currently access treatment on the NHS in England.

What UK patients are actually spending

The cost–adherence relationship

The UCL/BMC Medicine 2026 study identified cost as the single biggest driver of discontinuation. That has a clinical consequence, not just a financial one: a medicine that costs more than a patient can sustain will not deliver the long-term maintenance the evidence supports. The SURMOUNT-4 withdrawal data showing substantial weight regain after stopping is, in the UK private context, partly a cost problem as much as a biological one.

Who is using weight loss injections in the UK?

The UCL Smoking Toolkit Study provides the most comprehensive UK demographic picture of GLP-1 users to date.

The gender, age and income concentration

The 2:1 female-to-male ratio and 45–55 peak likely reflect both the prevalence of weight-related health concerns in that group and a greater willingness to engage with medical weight management. The socioeconomic concentration is the starkest finding in the UCL data. At current private prices, these medicines are largely inaccessible to the populations carrying the highest burden of obesity-related disease — which is a health inequality finding, not a market one.

Adherence, dropout and the rebound problem

Trial efficacy data assumes continued treatment. Real-world adherence data tells a different story, and understanding it is essential to setting realistic expectations.

The adherence gap

Trial retention and real-world retention are not comparable numbers, and the gap is largely explained by a variable trials do not expose participants to: paying for the medicine. This has a practical consequence for anyone starting treatment privately — the plan needs to cover the maintenance dose price, not the starting dose price, because starting and stopping repeatedly is a worse outcome than not starting.

It also means the quality of ongoing clinical support matters. Side effects that go unmanaged become reasons to stop; dose escalation done on a fixed schedule rather than on response produces avoidable symptoms. See our guide to restarting Mounjaro safely for patients who have stopped and want to return.

Counterfeit and black market: the safety data

The scale of the UK counterfeit weight loss injection problem is one of the most significant and under-reported patient safety issues in UK healthcare.

Red flags worth treating as absolute

• Any seller operating through Instagram, TikTok, Facebook groups or messaging apps
• Any offer to supply without a prescription or clinical assessment
• Imported pens not licensed for UK use, with no cold-chain guarantee
• Anyone else’s medication, however it is packaged
• Prices far below the market range — genuine UK-licensed stock has a wholesale cost

If you have already used a product bought outside the regulated route, speak to a pharmacist or your GP. If you have symptoms that concern you, contact NHS 111, or 999 in an emergency.

UK clinical outcomes data: what real-world results look like

Beyond the trials, a growing body of UK real-world evidence documents what these medicines achieve in ordinary practice.

Why real-world results are lower than trial results

NHS tier 3 outcomes (8–11%) sit well below STEP 1 trial outcomes for semaglutide. The reasons are well understood: trial populations are selected, supported and monitored at a level ordinary clinical practice cannot replicate. Real-world populations carry more comorbidity, more complex medication lists, less intensive lifestyle support, and the attrition that cost creates. That gap is one of the most important things for any patient to understand before starting.

Wegovy pill: MHRA approval, June 2026

On 11 June 2026 the MHRA approved oral semaglutide 25mg for weight management in the UK — the first daily oral weight loss tablet licensed in this country, and a genuinely new category in the UK market.

The significance is primarily about access rather than efficacy. For people who are needle-phobic, and for those who find weekly injection management difficult, the tablet removes the most commonly cited non-cost barrier to treatment. OASIS 4 phase 3 data reported average weight loss of 16.6% at 25mg over 64 weeks with full adherence.

For the full clinical guide see our Wegovy pill UK guide.

Pipeline medications: 2026 and beyond

This is the most significant period of innovation in obesity pharmacotherapy in decades. By 2028, UK patients are likely to have access to at least three distinct product categories — injectable GLP-1, injectable dual agonist, and oral GLP-1 — each with a meaningfully different efficacy and patient experience profile.

UK obesity statistics: the context behind the numbers

To understand why this market has grown so fast, it helps to see the scale of the underlying problem.

Why 2 million out of 15 million matters

Roughly 1 in 7.5 UK adults with obesity now accesses a GLP-1 medication through one route or another. That is remarkable penetration for a medicine class that barely existed in this indication three years ago. It also means around 13.5 million adults with obesity are not accessing these treatments — because of cost, awareness, NHS access barriers, clinical unsuitability or personal preference.

NHS cost and NICE economics: why access is rationed

NICE approved both semaglutide (TA875) and tirzepatide (TA1026) on the basis that they represent good value for the NHS in high-risk groups. The economics behind the rationing decision are worth understanding.

The phasing is a fiscal decision, not a clinical one. NICE’s analysis confirms cost-effectiveness; the NHS does not have the capacity to prescribe at the scale the eligible population implies. The parallel private market is the direct consequence.

UK market forecast: 2026–2028

Regulatory timeline: what changed in 2025–2026

The UK provider landscape

Two million private patients are spread across a fragmented provider market ranging from NHS-contracted pharmacies to unregulated sellers.

The medicine itself is identical regardless of source, provided it is genuine licensed stock from the authorised UK supply chain. What varies between providers is everything around it: the depth of the clinical assessment, who reviews your case, whether anyone checks in, how side effects are handled, and what happens when progress stalls. Comparing providers on price alone compares the identical component and ignores the variable one.

Social media and weight loss injections

Before-and-after content is overwhelmingly produced by patients documenting their own experience rather than by clinicians, and academic analysis finds high rates of omission of clinical information. For anyone whose first encounter with these medicines is through social media, the parts that matter most — dosing, side effects, cost over a year, monitoring — are the parts least likely to be represented.

UK vs international: how access compares

UK private pricing compares favourably with US out-of-pocket costs and sits broadly in line with other European markets. The phased, restricted NHS rollout is consistent with how most health systems are managing the budget impact — the difference is that England has a more formal and transparent phasing plan than most, which at least gives a visible timeline even if a long one.

The UK market in 10 statistics

What this data means for patients choosing a provider

1. A large market attracts variable quality

Two million patients is a large market, and large markets attract providers of widely varying quality — from rigorously governed pharmacies to platforms with minimal clinical oversight to outright counterfeit sellers. The MHRA seizure figures are not a peripheral problem; they describe a market where verification at the aggregate level is inadequate. Verify your provider’s registration independently.

2. The adherence problem is real, and support helps

Half of private patients stopping within a year, with cost the leading driver, represents a population-level failure to realise what these medicines can do. Regular clinical review — dose decisions based on response rather than a fixed schedule, side effects addressed when they appear, cost discussed openly before it becomes a reason to stop — is the part of the service that moves that number.

3. Counterfeit risk is not theoretical

18,300+ Border Force seizures and around 20 million MHRA-seized doses in a single year. Buying outside the regulated route is not a cost-saving strategy, it is a patient safety risk. GPhC registration is the statutory requirement and the one that matters most; LegitScript certification is a useful additional signal but not a substitute for statutory regulation.

4. The oral option changes the access equation

For needle-phobic patients, shift workers and frequent travellers, a daily tablet removes the most commonly cited non-cost barrier to treatment. It does not change the cost picture, which remains the dominant factor in whether people continue.

Methodology: how this guide is compiled

• Primary sources only. Every figure traces to a peer-reviewed publication, a regulator, a government body or a named academic institution. Where only secondary reporting exists, that is stated.
• Conflicts are shown, not resolved. Where two credible sources disagree — as UCL and IQVIA do on adoption — both figures appear with an explanation of the methodological difference.
• Derived figures are labelled. Percentages calculated from two published numbers are marked as calculated rather than presented as sourced.
• No estimates are invented. Where UK data does not exist, that gap is stated rather than filled with international data presented as UK data.
• Quarterly review. Figures are re-verified against their primary source each quarter, and the review date at the top of this page is updated only when that verification has actually been done.

Frequently asked questions

Summary

The UK weight loss injection market in 2026 is defined by three things: enormous private demand, a deliberately narrow NHS pathway, and an adherence problem driven mostly by cost. Over two million people are paying privately, most of them on tirzepatide, and around half of them will stop within a year.

For anyone reading this while deciding whether to start treatment, the most useful number on the page is not the two million. It is the 50%. Planning for the maintenance dose price rather than the starting dose price, and choosing a provider whose clinical support is real rather than nominal, are the two decisions most likely to determine whether treatment works out.

These are prescription-only medicines. This guide is general information and does not replace advice from a qualified healthcare professional, and treatment is supplied only after an individual clinical assessment by a UK-registered prescriber.

Related guides and treatment pages

References

1. UCL / BMC Medicine. Use of anti-obesity medications in the UK: a nationally representative survey (Smoking Toolkit Study). BMC Medicine, 2026. UCL press release
2. IQVIA. Out-of-Pocket Obesity Market UK. July 2025, via industry reporting.
3. BMJ. Freedom of Information investigation into NHS integrated care board tirzepatide prescribing, 2025.
4. MHRA — enforcement action against falsified and unlicensed weight loss products, 2025.
5. Border Force. Freedom of Information response — seizures of illegal weight loss and diabetes products, February 2024 to May 2025.
6. NICE TA1026 — Tirzepatide for managing overweight and obesity, 2025.
7. NICE TA875 — Semaglutide for managing overweight and obesity, 2023.
8. NICE NG246 — Overweight and obesity management.
9. NHS England — interim commissioning guidance, implementation of NICE TA1026.
10. NHS England — 2026/27 GP contract, weight management QOF indicator.
11. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038
12. Aronne LJ, Sattar N, Horn DB, et al; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945
13. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal: post hoc analysis of SURMOUNT-4. JAMA Intern Med. 2026;186(2):157–167. doi:10.1001/jamainternmed.2025.6112
14. Aronne LJ, Horn DB, le Roux CW, et al; SURMOUNT-5 Investigators. Tirzepatide as compared with semaglutide. N Engl J Med. 2025. doi:10.1056/NEJMoa2416394
15. Wharton S, et al. Once-weekly semaglutide 7.2mg (STEP UP). Lancet Diabetes & Endocrinology, 2025.
16. Novo Nordisk. MHRA approval of oral semaglutide for weight management. Press release, 11 June 2026.
17. GPhC — guidance for online pharmacies providing weight management medicines, updated February 2025.
18. Second Nature. Real-world semaglutide outcomes study. JMIR Formative Research, 2024.
19. NHS England / Health Survey for England 2024 — adult obesity and overweight prevalence.
20. Chemist-4-U. UK weight loss statistics and Google Trends analysis, February 2026.